Alice Shaw
MD, PhD
Vice President, Global Development
👥Biography 个人简介
Alice Shaw pioneered the clinical development of ALK and ROS1-targeted therapies and discovered key resistance mechanisms to crizotinib in ROS1-positive NSCLC. Her work on lorlatinib established it as an effective agent against ROS1 resistance mutations. She has transitioned from academic leadership at Mass General to industry drug development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Alice Shaw 的研究动态
Follow Alice Shaw's research updates
留下邮箱，当我们发布与 Alice Shaw（Novartis Oncology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment